Pemetrexed for treatment of advanced non-small cell lung cancer
- 1 February 2004
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 31, 100-105
- https://doi.org/10.1053/j.seminoncol.2003.12.001
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- O-271 Phase II randomized study of pemetrexed plus carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancerLung Cancer, 2003
- ALIMTA® (pemetrexed disodium) as second-line treatment ofnon-small-cell lung cancer: a phase II studyAnnals of Oncology, 2003
- Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinomaCancer, 2001
- Phase I and Pharmacologic Study of Sequences of Gemcitabine and the Multitargeted Antifolate Agent in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2000
- Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trialAnnals of Oncology, 2000
- Clinical and Pharmacokinetic Phase I Study of Multitargeted Antifolate (LY231514) in Combination With CisplatinJournal of Clinical Oncology, 1999
- MTA (LY231514) demonstrates clinical activity against malignant mesothelioma in a phase I combination trial with carboplatinEuropean Journal Of Cancer, 1999
- A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationCancer Chemotherapy and Pharmacology, 1999
- Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II StudyJournal of Clinical Oncology, 1999